secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001558370-24-008845
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure receives FDA RMAT designation for gene therapy AMT-130 in Huntington's disease
--------------------------------------------------------------------------------

- FDA granted RMAT designation for AMT-130 based on 24-month Phase I/II data vs. natural history cohort.
- First RMAT designation ever for a Huntington's disease therapy, enabling fast track and breakthrough therapy benefits.
- Designation allows increased collaboration with FDA on accelerated approval pathways and expedited development.
- uniQure expects to provide updated interim data from Phase I/II studies in mid-2024, including up to 3-year follow-up on 29 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024008845/0001558370-24-008845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024008845/qure-20240603x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer